CN102103142B - Tafi含量的体外检测方法 - Google Patents
Tafi含量的体外检测方法 Download PDFInfo
- Publication number
- CN102103142B CN102103142B CN 201010612757 CN201010612757A CN102103142B CN 102103142 B CN102103142 B CN 102103142B CN 201010612757 CN201010612757 CN 201010612757 CN 201010612757 A CN201010612757 A CN 201010612757A CN 102103142 B CN102103142 B CN 102103142B
- Authority
- CN
- China
- Prior art keywords
- tafi
- antibody
- sample
- pamam
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000201 Carboxypeptidase B2 Proteins 0.000 title claims abstract description 138
- 238000000034 method Methods 0.000 title claims abstract description 43
- 102000003847 Carboxypeptidase B2 Human genes 0.000 title abstract description 10
- 238000000099 in vitro assay Methods 0.000 title abstract 5
- 238000002965 ELISA Methods 0.000 claims abstract description 57
- 229920000962 poly(amidoamine) Polymers 0.000 claims abstract description 54
- 238000001514 detection method Methods 0.000 claims abstract description 52
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 31
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000243 solution Substances 0.000 claims abstract description 25
- 239000003085 diluting agent Substances 0.000 claims abstract description 15
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000003556 assay Methods 0.000 claims abstract description 8
- 102100035023 Carboxypeptidase B2 Human genes 0.000 claims description 128
- 239000000523 sample Substances 0.000 claims description 72
- 239000007788 liquid Substances 0.000 claims description 50
- 239000000427 antigen Substances 0.000 claims description 45
- 102000036639 antigens Human genes 0.000 claims description 45
- 108091007433 antigens Proteins 0.000 claims description 45
- 210000002381 plasma Anatomy 0.000 claims description 28
- 239000012895 dilution Substances 0.000 claims description 25
- 238000010790 dilution Methods 0.000 claims description 25
- 238000007865 diluting Methods 0.000 claims description 24
- 102000004190 Enzymes Human genes 0.000 claims description 20
- 108090000790 Enzymes Proteins 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 239000007790 solid phase Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 14
- 239000003599 detergent Substances 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 12
- 238000013016 damping Methods 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 10
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims description 8
- 230000031700 light absorption Effects 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 238000005259 measurement Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229940098773 bovine serum albumin Drugs 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 239000008273 gelatin Substances 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 230000002779 inactivation Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 101100433727 Caenorhabditis elegans got-1.2 gene Proteins 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 101000946518 Homo sapiens Carboxypeptidase B2 Proteins 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052698 phosphorus Inorganic materials 0.000 claims description 3
- 239000011574 phosphorus Substances 0.000 claims description 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 3
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 239000012086 standard solution Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 102100033195 DNA ligase 4 Human genes 0.000 claims description 2
- 101000927810 Homo sapiens DNA ligase 4 Proteins 0.000 claims description 2
- 238000002844 melting Methods 0.000 claims description 2
- 230000008018 melting Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 11
- 238000000338 in vitro Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 2
- 238000003149 assay kit Methods 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- 238000004140 cleaning Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012089 stop solution Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 18
- 229940088598 enzyme Drugs 0.000 description 16
- 208000026106 cerebrovascular disease Diseases 0.000 description 13
- 230000002526 effect on cardiovascular system Effects 0.000 description 13
- 208000024172 Cardiovascular disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000003527 fibrinolytic agent Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003480 fibrinolytic effect Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 201000008247 brain infarction Diseases 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- SENLDUJVTGGYIH-UHFFFAOYSA-N n-(2-aminoethyl)-3-[[3-(2-aminoethylamino)-3-oxopropyl]-[2-[bis[3-(2-aminoethylamino)-3-oxopropyl]amino]ethyl]amino]propanamide Chemical compound NCCNC(=O)CCN(CCC(=O)NCCN)CCN(CCC(=O)NCCN)CCC(=O)NCCN SENLDUJVTGGYIH-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical group N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000005367 Carboxypeptidases Human genes 0.000 description 3
- 108010006303 Carboxypeptidases Proteins 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 238000006845 Michael addition reaction Methods 0.000 description 2
- 208000002151 Pleural effusion Diseases 0.000 description 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- -1 amide compound Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010339 medical test Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- DGLRDKLJZLEJCY-UHFFFAOYSA-L disodium hydrogenphosphate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O DGLRDKLJZLEJCY-UHFFFAOYSA-L 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- LTUDISCZKZHRMJ-UHFFFAOYSA-N potassium;hydrate Chemical compound O.[K] LTUDISCZKZHRMJ-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010612757 CN102103142B (zh) | 2010-12-30 | 2010-12-30 | Tafi含量的体外检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010612757 CN102103142B (zh) | 2010-12-30 | 2010-12-30 | Tafi含量的体外检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102103142A CN102103142A (zh) | 2011-06-22 |
CN102103142B true CN102103142B (zh) | 2013-08-14 |
Family
ID=44156072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010612757 Active CN102103142B (zh) | 2010-12-30 | 2010-12-30 | Tafi含量的体外检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102103142B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103728453B (zh) * | 2014-01-26 | 2016-05-25 | 辽宁迈迪生物科技有限公司 | 一种tafi含量的体外检测试剂盒及其检测方法 |
CN103760352B (zh) * | 2014-01-26 | 2015-09-30 | 辽宁迈迪生物科技有限公司 | 一种用于tafi含量体外检测的试剂盒及其体外检测方法 |
CN109682967B (zh) * | 2018-12-17 | 2021-12-28 | 暨南大学 | Pamam在制备用于免疫检测的试剂中的应用 |
CN110632324A (zh) * | 2019-09-25 | 2019-12-31 | 百盛(广州)生物制品有限公司 | 用于二抗检测系统的聚酰胺胺结构多聚物及其制备方法 |
CN112592385B (zh) * | 2020-12-02 | 2023-02-03 | 杭州百凌生物科技有限公司 | 一种人工多肽组合物、其抗体及在病理检测中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070003552A1 (en) * | 2002-07-09 | 2007-01-04 | Gebbink Martijn F B | Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation |
ATE464393T1 (de) * | 2002-08-29 | 2010-04-15 | American Diagnostica Inc | Diagnostischer assay für den mit thrombin aktivierbaren fibrinolyse-inhibitor (tafi) |
JP2005287503A (ja) * | 2004-04-01 | 2005-10-20 | Aventis Pharma Deutschland Gmbh | TAFI−Ile347多型を決定することによって血栓形成性障害に関する危険性を同定する方法 |
CN1296711C (zh) * | 2004-05-14 | 2007-01-24 | 沈阳迈迪生物医学技术有限公司 | 乳腺癌的Her-2免疫组织化学诊断试剂盒 |
-
2010
- 2010-12-30 CN CN 201010612757 patent/CN102103142B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102103142A (zh) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20020132370A1 (en) | Detection of a blood coagulation activity marker in a body fluid sample | |
JP5554247B2 (ja) | ヒト体液中のシスタチンc測定方法 | |
CN102103142B (zh) | Tafi含量的体外检测方法 | |
CN102183635A (zh) | Tafi含量的体外检测试剂盒 | |
CN108152512A (zh) | 肝素结合蛋白检测试剂盒及其制备方法 | |
CN102680676A (zh) | 髓过氧化物酶(myeloperoxidase MPO)测定试剂盒(胶乳增强免疫比浊法) | |
ES2366043T3 (es) | Procedimiento para analizar inmunológicamente el producto de la degradación con plasmina de la fibrina estabilizada. | |
WO2006123789A1 (ja) | 酵素分析方法 | |
JPH09178740A (ja) | 糖尿病または糖尿病合併症用マーカーとしての使用 | |
US20030138844A1 (en) | Antibodies binding a gamma carboxyglutamic acid displaying epitope | |
EP0095286B1 (en) | Immunoassay | |
CN102928407A (zh) | 检测阿维菌素类药物的磁颗粒化学发光试剂盒及其应用 | |
Kwon et al. | Sensing performance of protein C immuno-biosensor for biological samples and sensor minimization | |
CN103728453A (zh) | 一种tafi含量的体外检测试剂盒及其检测方法 | |
JP2001354700A (ja) | モノクロ−ナル抗体及びヒトフィブリン分解産物の測定方法 | |
JP2997520B2 (ja) | 血栓及び凝固亢進状態の診断及び検査のための生物学的試料からのd―ダイマーの直接化学結合的方法 | |
JP3345507B2 (ja) | アシアログリコプロテインレセプターの測定法及びこれに用いる測定試薬 | |
JPH04203967A (ja) | 微量成分の迅速測定方法 | |
JPH02503033A (ja) | インビトロ診断法およびそのために有用な手段 | |
CN101176000A (zh) | 用于测定糖蛋白Ibα(GPIBα)蛋白质的方法 | |
JP2515533B2 (ja) | 蛋白の定量方法 | |
JP3036545B2 (ja) | モノクローナル抗体とこれを産生するハイブリドーマ細胞株、およびこれを用いる免疫学的測定法 | |
CN118258990A (zh) | 检测试剂盒及其应用 | |
KR20230166100A (ko) | 고감도의 면역학적 측정 시약 및 측정 방법 | |
WO2001098782A1 (fr) | Kit de determination du pouvoir de coagulation du sang |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 117004 Liaoning Province, Benxi City Economic Development Zone Cladrastis road 166 Patentee after: Liaoning Maidi biological Polytron Technologies Inc Address before: 110179 Liaoning province Shenyang Hunnan New Long Street No. 7 building B room 306 Patentee before: Liaoning Maidi Biologic Technology Co., Ltd. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: In-vitro assay method for thrombin-activatable fibrinolysis inhibitor (TAFI) content Effective date of registration: 20190505 Granted publication date: 20130814 Pledgee: Chaoyang Bank Co., Ltd. Benxi Branch Pledgor: Liaoning Maidi biological Polytron Technologies Inc Registration number: 2019210000013 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200513 Granted publication date: 20130814 Pledgee: Chaoyang Bank Co., Ltd. Benxi Branch Pledgor: LIAONING MEDI BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: 2019210000013 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: In-vitro assay method for thrombin-activatable fibrinolysis inhibitor (TAFI) content Effective date of registration: 20200514 Granted publication date: 20130814 Pledgee: Chaoyang Bank Co., Ltd. Benxi Branch Pledgor: LIAONING MEDI BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2020210000020 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210601 Granted publication date: 20130814 Pledgee: Chaoyang Bank Co.,Ltd. Benxi Branch Pledgor: LIAONING MEDI BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2020210000020 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |